Genetic Aspect of Headache by Edgünlü, Tuba Gökdoğan & Çelik, Sevim Karakas
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 1
Genetic Aspect of Headache
Tuba Gökdoğan Edgünlü and Sevim Karakas Çelik
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/66852
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Tuba Gökdoğan Edgünlü and Sevim Karakas 
Çelik
Additional information is available at the end of the chapter
Abstract
Headache is a multifactorial disease and the genetic basis is not clear yet. We review 
recent findings about molecular basis of subtypes of headache. The fundamentals of 
molecular genetics and the recent advances in this area are important for clinicians to 
understand the pathogenesis of the disorder. Recent studies provide a foundation for 
critical appraisal of the literature, unprecedented insights and reveal promising treat‐
ment targets for future drug development. This chapter provides an overview of molecu‐
lar genetics, epigenetic and genome‐wide association studies on headache. In summary, 
we try to explain the state‐of‐the‐art molecular basis of headache and the possible future 
direction in this field of research studies. According to recent studies the main types 
of are evaluative, exploratory about molecular basis of headache. In recent years, new 
studies have been designed to provide an update and understanding of the modern day 
genetics, the advances in genetic research and methods and a basis for understanding 
the strategy by which advances in molecular genetics can be applied for understanding 
complex polygenetic diseases such as migraine.
Keywords: headache, genetic, epigenetic, cluster type headache, tension type headache, 
migraine
1. Molecular basis of headache subtypes
Recently, researchers have identified the gene variations that increase the susceptibility to 
develop headaches. To analyze the cause, clinical history of headaches is very important. 
While headaches can be caused by medical conditions, injuries, or infections, sometimes they 
are not due to any specific disease or other identified medical conditions. The three most 
common of those types of primary headaches are tension, cluster and migraine headaches 
(Figure 1). Tension‐type headache (TTH) brought on by stress or depression, so everyone has 
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experienced TTH. TTH can be brief, episodic or continuous. According to some researchers, 
TTH could be secondary to the vasoconstriction, rather than dilatation [1–3].
The neurobiological mechanisms of tension‐type headache are concerning. Central sensitiza‐
tion plays a major role in chronic TTH. Whether peripheral mechanisms or central mechanisms 
are primarily responsible for TTH is an important issue to differentiate it pathophysiologi‐
cally from migraine. The literature suggests that migraine and tension‐type headache may 
have the similar pathophysiology. Moreover, exact mechanism for both the disorders is still 
to be elucidated [4–6].
The prevalence of migraine has been shown to be increasing. The researchers have suggested 
that the central nervous system (CNS) susceptible to headache has been linked to an impor‐
tant survival or reproductive advantage. Some possible reasons are determined; one of these 
says that migraine is a defense mechanism; the other one consider it as a result of novel envi‐
ronmental factors; the next one regards migraine as a compromise between genetic harms and 
benefits. Genetic epidemiological studies are necessary to prove the involvement of genetic 
factors. Twin studies have been used to assess the respective roles of genetic and environmen‐
tal factors in migraine [7, 8].
We briefly mention here the headache types and characteristics. The first title is TTH. 
Biological mechanisms of TTH are yet to be explained. This disease usually is associated with 
depression and anxiety. In addition, the genetic factors are most important for TTH patho‐
genesis. The neurological mechanisms of TTH are not known clearly. Genetic and neurobio‐
logical research studies have increased our understanding of the complex mechanisms that 
may lead to TTH. There is strong evidence for a genetic predisposition for TTH. Moreover 
pain pathways in the central nervous system are positively associated with TTH. Research 
has enhanced our current understanding regarding the means through which psychological 
factors lead to TTH, suggesting sympathetic hyperactivity as a possible mechanism [9, 10].
The etiology of cluster‐type headache (CH) is still unknown. Until recently, researchers 
thought that CH was not an inherited disorder; however, several new studies have suggested 
Figure 1. Diagram of primary headaches subtypes.
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that genetic factors play an important role in the CH. Some studies show that CH phenotype 
is inherited such as in autosomal dominant disease [11, 12]
To identify genetic factors that confer susceptibility to migraine, many studies have been con‐
ducted on the genetic basis of migraine types. First approach on this is classical linkage analysis. 
This approach aims to identify affected segments of chromosomes in individuals using a family‐
based approach. For monogenic migraine types, this approach has been particularly successful. 
A second commonly used strategy to identify gene variants involves candidate‐gene association 
studies. These studies are determinate with alleles and genotype frequencies in control and case 
groups. Recently, DNA variants have advanced spectacularly, allowing the cost‐effective analy‐
sis of DNA variants in patients in so‐called genome‐wide association studies (GWAS). Also, 
GWAS included hundreds of genes for many complex diseases. To determine the size of rarer 
gene variants is too expensive and takes more time. Instead, methods such as next‐generation 
sequencing of exons (exome sequencing) and whole‐genome sequencing can be used [13].
2. Genetic aspects of tension‐type headache
While tension‐type headaches (TTH) are the most common primary headache disorder it has 
not been as thoroughly investigated as migraine headaches. A lifetime prevalence of TTH 
has been seen in the general population ranging between 30 and 78% in different studies 
[13]. Nevertheless, 24–37% had TTH several times a month, 10% had it weekly and 2–3% 
of the population had chronic TTH, usually lasting for the greater part of their lifetime [14] 
According to the second edition of the International Classification of Headache Disorders, 
TTH is classified into three subtypes according to headache frequency: infrequent episodic 
TTH, frequent episodic TTH and chronic TTH [13]. The female‐to‐male ratio of TTH is 5:4 
indicating that, unlike migraine, women are affected only slightly more than men [15]. The 
average age of onset of TTH is higher than in migraine, namely 25 to 30 years in cross‐sec‐
tional epidemiologic studies [16].
Many studies probably provide a valid measure of the major etiologic role that genetic or envi‐
ronmental factors play in TTH. Table 1 shows the genetic association studies in TTH. In a study 
of twins from the New Danish Twin Registry, it was found that the concordance rates were 
significantly higher in MZ than same‐gender DZ twin pairs with no or frequent episodic TTH, 
while the difference was not significant in chronic TTH due to small number of twin pairs. In 
monozygotic (MZ) and same‐gender DZ twin pairs, the concordance rates of infrequent epi‐
sodic tension‐type headache was significantly different in women but not in men, although the 
difference was small in both genders. It was suggested that genetic factors play a role in no and 
frequent episodic tension‐type headache, while infrequent episodic TTH is caused primarily by 
environmental factors [17]. However, differently Ulrich et al. suggested that an environmental 
influence was of major importance for episodic TTH and a genetic factor had minor contribu‐
tion [18] but in chronic tension‐type headache, the genetic factor may be more important.
When the population‐relative risk in first‐ degree relatives compared with normal controls 
has been calculated in a Danish study, it was shown that first‐degree relatives of 122 pro‐
bands with chronic tension headache had more than three times the risk of chronic tension 
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headache than the general population. An increased family risk can be caused by genetic 
or environmental factors because probands and spouses share their environment, the risk 
of chronic tension headache in spouses is used to elucidate the relative role of genetic and 
environmental factors. As first‐degree relatives had a significantly increased risk of chronic 
tension headache and spouses had no increased risk, this result supports the importance of 
genetic factors in chronic tension headache. [19]. For investigation of the mode of inheritance 
of chronic tension‐type headache complex segregation analysis was performed in 122 Danish 
families. The complex segregation analysis indicates that chronic tension‐type headache has 
multifactorial inheritance [20].
Because TTH treatment features medication with inhibitors for selective reuptake of serotonin 
and monoamine oxidase inhibitors, The polymorphic patterns of MAOA and MAOB, both in 
TTH patients and the healthy population were addressed in our previous study. MAO gene 
polymorphisms were examined in a group of 120 TTH patients and in another 168 unrelated 
healthy volunteers (control group). MAOA promoter and MAOB intron 13 polymorphisms 
were genotyped using PCR‐based methods. But an overall comparison between genotype 
and allele frequencies of the patients and the control group did not reveal any statistically 
significant difference between the patients and the control group [21].
Gene Genetic variants Results Reference
Monoamine oxidase (MAO) rs1799836 G/A promoter 
polymorphism of a variable  
number of tandem repeats  
(VNTR)
No association [21]
Catechol‐O‐methyltransferase 
(COMT)
Val158Met may be involved in the 
phenotypic expression
[25]
Tumor necrosis factor (TNF) TNFA 308G > A and TNFB 252G > A No association [40]
Estrogen receptor (ESR1)
progesterone receptor (PROGINS)
ESR1 PvuII (rs2234693), ESR1 325 
C→G (rs1801132)] and [(rs1042838)
No association [119]
Apolipoprotein E (APOE) Association [28]
Serotonin (5‐hydroxytryptamine, 
5HT) transporter gene
the variable number of tandem 
repeats (VNTR) and 5'‐flanking 
promoter region (5‐HTTLPR)
Association [33]
Serotonin transporter gene 5‐HTTLPR) Association [34]
Serotonin transporter gene 5‐HTTLPR Association [35]
Serotonin transporter gene 5HTR2c‐Cys23Ser No association [36]
Glutathione S‐transferase (GST) 
M1, T1, P1
GST M1 and T1 null polymorphism
GSTP1 Ile105Val
No Association [42]
Methylenetetrahydrofolate 
reductase gene (MTHFR)
C677T and A1298C Association [38]
Methylenetetrahydrofolate 
reductase gene (MTHFR)
C677T No association [39]
Table 1. The genetic association studies in TTH.
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The catechol‐O‐methyltransferase (COMT) is an enzyme involved in the metabolic degra‐
dation of dopamine, norepinephrin and epinephrine [22]. It is accepted that COMT gene is 
one of the several potential headache genetic determinants. Several studies indicate that the 
genetic polymorphism due to a G→A substitution at codon 158 of the COMT gene, which 
leads to the formation of a heat‐stable, high‐activity COMT variant (Val/Val) and heat‐labile, 
low‐activity variants (Val/Met or Met/Met) [23]. Zubieta et al. demonstrated that a measure of 
pain sensitivity paralleled the COMT activity of the genotypes and individuals with Val/Val 
genotype have reduced pain sensitivity compared with those with the Met/Met genotype [24]. 
And also, Fernández‐de‐las‐Peñas C et al. investigate the relationship between Val158Met 
polymorphisms, headache and pressure hypersensitivity in children with chronic tension‐
type headache (CTTH). But it was reported that the Val158Met COMT polymorphism does 
not appear to be involved in predisposition to suffer from CTTH in children; nevertheless, this 
genetic factor may be involved in the phenotypic expression, as pressure hypersensitivity was 
greater in those CTTH children with the Met/Met genotype [25]. Nitric oxide has an impor‐
tant role in the pathophysiology of tension‐type headache. It is suggested nitric oxide synthe‐
tase inhibitors are helpful in the management of chronic tension‐type headache by reducing 
the central sensitization [26]. Besides nitric oxide synthetase, nitric oxide production is also 
dependent on apolipoprotein E (APOE) polymorphism and this production is gene specific 
[27]. And it was investigated that APOE polymorphism may be associated with migraine as 
well as tension‐type headache. And the results of the study showed that APOE epsilon2 gene 
increases the risk of migraine, while APOE epsilon4 gene is protective against migraine and 
tension‐type headache [28].
As other neurotransmitters, serotonin have a role in pain mechanisms, selective serotonin 
re‐uptake inhibitors (SSRIs) reduce the symptomatic/analgesic medication use for acute head‐
ache attacks of tension‐type headache [29]. Serotonin is taken up from the synaptic space 
regularly with a 5‐hydroxytryptamine transporter (5‐HTT) [30, 31]. Two polymorphic sites 
in 5‐HTT gene was studied in various studies: different numbers of variable‐number‐tandem‐
repeat (VNTR) region of 16‐17 base‐pair (bp) in the second intron of 5‐HTT gene leads several 
alleles such as STin 2.7, STin 2.9, STin 2.10, STin 2.11, STin 2.12 and a 44‐base pair inser‐
tion/deletion in the 5'‐‐flanking promoter region (5‐HTT gene‐linked polymorphic region‐5‐
HTTLPR) creating a short (S) and a long (L) allele [32]. The possible role of 5‐HTTLPR and 
VNTR polymorphisms was evaluated individually and in combination in risk of CTTH. 
Moreover, the relationship between the clinical response of the drugs or analgesic overuse 
and the serotonin transporter (5‐HTT) gene polymorphisms was investigated [33, 34]. Park et 
al. reported that S/S genotype frequency was significantly higher in patients with CTH (76%) 
than in those with controls (59%; P =.02). The authors suggested that 5‐HTTLPR might be one 
of the genetically contributing factors [35].
But differently in another study any statistically significant results based on the 5‐HTTLPR 
gene alleles and CTTH risk were not found. Only, when it was investigated the combined 
effect of the two polymorphic loci of the 5‐HTT gene, genotypes S/S‐12/10 and L/S‐12/10 dis‐
played statistically significant frequency in the CTTH group than in the control group. Aylin 
et al. reported that the presence of homozygous L and STin12 alleles may play a protective 
role against CTTH [33]. Also in a different study showed that the S/S genotype frequency 
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was significantly higher in CTTH patients with analgesic overuse. And it was suggested that 
serotonergic activity may be involved in the development of analgesic overuse in CTTH and 
that 5‐HTTLPR might be one of the genetically contributing factors [34]. But no significant 
differences were noticed between the 5‐HTTLPR and VNTR haplotype groups and success in 
treatment. 5HT2c‐receptor (5HTR2c) is another subtypes of 5HT2 families. The relationship 
between 5HTR2c Cys23Ser polymorphism and TTH was also investigated. However, there 
were no differences found among TTH and control groups [36].
Increased homocysteine levels are associated with various pathological conditions in humans, 
including stroke and cardiovascular disorders. So vasodilation of cerebral blood vessels may 
result in headache, or high levels of homocysteine may cause temporary thrombosis of cere‐
bral blood vessels, allowing less oxygen into the brain thus possibly causing headache. Frosst 
et al. reported an association between the homozygous C677T mutation in the 5,10‐methy‐
lenetetrahydrofolate reductase (MTHFR) gene and serum homocysteine levels [37]. In a case‐
control study, the prevalence of two common MTHFR polymorphisms, C677T and A1298C, 
in tension‐type headache patients and healthy controls was compared. And it was suggested 
that patients with C1298C and C677C/C1298C genotypes may predispose to tension‐type 
headache [38]. On the contrary, the study of Kowa et al. could not reach the same results. It 
was reported that MTHFR gene polymorphisms was not a genetic risk factor for TTH in their 
study [39].
Also it was investigated the relationship between TTH and tumor necrosis factor (TNF) 
gene polymorphisms (TNFA 308G > A and TNFB 252G > A) [40] and also estrogen receptor 
[ESR1 PvuII (rs2234693), ESR1 325 C→G (rs1801132)] and progesterone receptor [PROGINS 
(rs1042838)] polymorphisms [41]. But no risk was observed when TTH patients were com‐
pared with HC. Similarly, in a study that evaluates the relationship between GSTM1, T1 and 
P1 gene polymorphism and TTH, no difference was found between two groups in the geno‐
type and allele distribution [42].
3. Genetic aspects of cluster‐type headache
Cluster headache (CH), the most severe primary headache, is characterized by recurrent, uni‐
lateral attacks of headache of great intensity and brief duration, accompanied by local signs 
and symptoms of autonomic dysfunction. In about 80% of the patients, the attacks occur in 
series lasting weeks or months, so‐called cluster periods [3]. The disease has an estimated 
prevalence of 1/500 and displays marked sex bias (female:male ratio 1:2.5 to 1:3.5) [43, 44].
Twin studies represent one of the simplest ways to unravel the relative importance of genetic 
and environmental effects. Much of the available literature on CH is reported in numerous 
concordant monozygotic twin pairs [45–48]. However, other studies demonstrated discordant 
twin pairs showed the importance of both genetic and individual specific factors and environ‐
mental factors in CH [49]. Beside this, epidemiological surveys indicate that compared with 
the general population, the first‐degree relatives of CH patients had a 14 fold increase in the 
disease risk in affected Danish probands and 39 fold increase in affected Italian probands. 
Current Perspectives on Less-known Aspects of Headache8
Also second‐degree relatives have two times higher risk in Danish probands and eight times 
higher risk in Italian probands [50–52]. The different results can be partly explained by meth‐
odological differences or selection bias. The increased familial risk of CH strongly suggests 
a genetic cause for the disease. However, the pattern of inheritance does not appear to be 
uniform. The familial clustering supports a model of autosomal dominant inheritance with 
reduced penetrance in some families but autosomal recessive model in others [53, 54] Also a 
study by Sjöstrand demonstrated a significantly lower mean age of onset in the second/third 
generation of families with CH than in the first generation. This can be explained by anticipa‐
tion or selection bias, since individuals with late age at onset from the second/third generation 
may not yet have symptoms [55, 56].
To date, no clear molecular genetic evidence has been shown for CH. A point mutation was 
reported in mitochondrial transfer RNAleu(UUR) gene at nucleotide pair 3243 in a Japanese 
man with sporadic CH [56]. However, this mutation was not detected in Italian and German 
patients with CH [57, 58] and the involvement of mitochondrial genes in CH remains unproven.
Neuroimaging studies have identified the posterolateral hypothalamic grey matter as the key 
area for the basic defect in CH [59]. Hypocretin‐1 and ‐2 (also called orexin‐A and ‐B) are 
newly discovered neuropeptides [60, 61]. Hypocretin‐containing cells are located exclusively 
in the posterolateral hypothalamus, with widespread projections to the entire neuroaxis. 
Hypocretin‐1 and ‐2 bind to 2 G protein‐coupled receptors, termed HCRTR1 and HCRTR2. 
The peptides of the hypocretin/orexin system influence a wide range of physiologic and 
behavioral processes in mammals [62, 63]. Some of these, such as sleep, neuroendocrine, loco‐
motor, autonomic regulation, feeding behavior and energy homeostasis, may be of relevance 
for the pathogenesis of CH. Also a striking feature of CH is its diurnal and seasonal period‐
icity, suggesting that circadian and infradian rhythms regulate CH attacks. The hypocretin 
system plays a pivotal role in generating such rhythms and hypocretin‐containing neurons 
originate almost exclusively from the posterolateral hypothalamus [60, 61, 64]. Recent studies 
suggest a contribution of hypocretin to the pathogenesis of CH. A study among 109 Italian 
CH patients showed a strong association between the hypocretin type 2 receptor (HCRTR2) 
G1246A polymorphism and CH [65]. This association was confirmed in a major study from 
Germany, showing that homozygous carriers of the G‐allele had a twofold increase in disease 
risk [66]. Also in another study among Italian patients five additional intronic polymorphisms 
was genotyped, covering more than 75% of the entire 108.35 kb sequence of the HCRTR2 
gene. And the carriage of the GTAAGG haplotype was shown to be associated with the dis‐
ease and resulted in a 3.7‐fold increased risk for CH [67]. On the contrary, the association 
was not replicated in a dataset of CH patients of Danish, Swedish and British origin [68]. In 
addition there are two published meta‐analysis studies investigating the association between 
polymorphisms of the HCRTR2 gene and CH. However, there are conflicting results between 
two studies, Rainero et al. suggested that the G1246A polymorphism of the HCRTR2 gene 
may modulate the genetic risk for CH [69] but Weller et al. did not find evidence for associa‐
tion of G1246A polymorphism (rs2653349) [70].
Besides this, the association between CH and a variable number tandem repeat (VNTR) 
polymorphism of the PER3 clock gene that has been associated to preferred daily rhythm 
Genetic Aspect of Headache
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(chronotype) in several studies was investigated. The hypothalamic biological clock may thus 
be involved in the pathophysiology and 149 patients were genotyped, but no difference in 
PER3 VNTR polymorphisms between patients and controls was found. And no association 
between CH, PER3 VNTR polymorphism and chronotype was found in the study [71].
Also some researchers performed a genetic association study to evaluate the relationship 
between CH and polymorphisms in the Clock gene, another highly conserved circadian gene, 
that influence the circadian phase in humans [72]. But they found that phenotype and allele 
frequencies were similarly distributed in CH patients and controls. Also it was determined 
that the clinical features of the disease were not significantly influenced by different geno‐
types. In conclusion, studies reported that the 3092 T‐‐>C polymorphism of the Clock gene is 
unlikely to play an important role in CH [73, 74].
Recent studies suggested that iron metabolism may be involved in the pathophysiology of 
primary headaches. The genetic association studies are shown in Table 2. In patients with 
migraine and chronic daily headache, Welch and colleagues [75] reported elevated iron con‐
centrations in the periaqueductal gray matter, one of the pain‐modulating centers of the 
brainstem. To evaluate whether mutations of the HFE gene would modify the occurrence 
and the clinical features of CH, an association study was performed in a cohort of Italian CH 
patients and healthy controls. They did not find C282Y mutation in both controls and cases. 
The prevalence of the H63D mutation was nearly similar in controls and cases so it was sug‐
gested that genetic variations within the HFE gene are associated with CH. But the HFE D63D 
genotype determined showed the onset of the disease at a significantly later age in compari‐
son with both H63H and H63D patients. So they recommended the HFE gene may influence 
the disease phenotype and may be regarded as a disease modifier gene [76].
Nitric oxide (NO) plays a critical role in the regulation of vasodilation, neurotransmission, 
inflammation and many other events throughout the body. NO also appears to be an impor‐
tant mediator of vascular headache pathophysiology [77, 78]. And an association analysis 
of five polymorphic microsatellite markers in the three different NO synthase (NOS) genes; 
nNOS (NOS1), iNOS (NOS2A) and eNOS (NOS3) was performed. However, it is unlikely that 
genetic variations within the NOS genes contribute greatly to CH susceptibility [79].
Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the remethylation path‐
way converting homocysteine to methionine. The TT genotype of the common MTHFR 
677C>T polymorphism (rs1801133) has been shown to impair enzyme activity and increase 
homocysteine levels [37]. It was shown that this variant has been linked to migraine in recent 
meta‐analyses [80, 81] Homocysteine and oxidized metabolites like homocysteic acid exert 
excitatory effects on neurons and homocysteic acid has been shown to increase cell firing of 
trigeminal neurons [82]. Hence, a link between the MTHFR 677C>T polymorphism and CH 
is plausible. But in an investigation on the association between the MTHFR 677C>T polymor‐
phism and CH among German patients and controls do not indicate an association between 
genotypes of the MTHFR 677C>T polymorphism and CH overall [83].
Alcohol is a well‐known trigger factor for CH attacks during the active phases of the disease. 
The alcohol dehydrogenase (ADH) pathway, which converts alcohol to the toxic substance 
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Gene Genetic variants Results Reference
Alcohol dehydrogenase  
4 (ADH4)
rs1800759 (‐136AC)
rs1126671 (Ile328Val)
No association [85]
Period (PER3) VNTR polymorphism No association [71]
Hypocretin receptor 2 
(HCRTR2)
G1246A (rs2653349) No association [70]
5‐HTTLPR rs4795541 (3‐bp insdel) rs25531 
(A > G)
No association
Alcohol dehydrogenase 
(ADH4)
rs1800759 (‐136AC)
rs1126671
(Ile328Val)
Association [84]
Methylenetetrahydrofolate 
reductase gene (MTHFR)
rs1801133 (677C>T) No association [83]
Hypocretin Receptor‐2 
(HCRTR2)
Haplotype of rs10498801, 
rs3122156, rs9357855, rs2653342,
rs3800539,
rs2653349
Association [67]
CLOCK Gene rs1801260 (T3092C) No association [73]
HCRTR2 G1246A (rs2653349) Association [69]
HCRTR2 G1246A (rs2653349) No association with drug 
responses in CH
G protein beta3 subunit rs5443
(C825T)
Association with triptan 
response
[87]
Hypocretin receptor 2 
(HCRTR2)
G1246A (rs2653349) Association
Clock gene rs1801260 (T3092C) No association [76]
Calcium channel gene 
(CACNA1A)
SSCP analysis of all 47 exons No association [89]
Calcium channel gene 
(CACNA1A)
No association [88]
HFE (hemochromatosis) C282Y and H63D No association [76]
Hypocretin (HCRT)
Hypocretin receptor 
(HCRTR1)
Hypocretin receptor 2 
(HCRTR2)
‐3250CT
rs8072081
(‐1717CT)
rs1056526
(T264C)
rs2271933
(C1375T)
rs2653349
(G1246A)
rs1027650
(IVS4 12.564AC)
Not polymorphic
Not polymorphic
No association
No association
Association
No association
[65]
Table 2. The genetic association studies in CH.
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acetaldehyde, is responsible for most of the alcohol breakdown in the liver. And Rainero and 
colleagues investigated the association of genetic variants within the ADH4 gene with CH 
susceptibility and phenotype. They suggested that CH was associated with the ADH4 gene or 
a linked locus. For rs1126671 polymorphism, the carriage of the AA genotype, in comparison 
with remaining genotypes, was associated with a significantly increased disease risk of 2.33 
times. [84] But the results were not confirmed in Swedish population. The data from this study 
did not support an association of the ADH4 SNPs rs1126671 and rs1800759 with CH [85].
Only about 70% of migraine and CH patients report significant treatment responses to triptans, 
which are agonists at 5‐HT1B/D receptors belonging to the family of G protein‐coupled recep‐
tors. A C825T polymorphism identified in the gene for the G protein β3 (Gβ3) subunit (GNB3) 
has been associated with an enhanced signal transduction via GPCR [86]. It was investigated 
whether a common polymorphism in the gene for the G protein β3 subunit (GNB3 C825T) modu‐
lates responder rates to triptans among a large cohort of Caucasian CH patients. It was suggested 
that pain relief by triptans is significantly modulated by a common genetic GNB3 variant [88].
Also mutations of the P/Q type calcium channel alpha 1 subunit (CACNA1A) gene on chro‐
mosome 19p13 have been shown to cause several neurological disorders with a wide clinical 
spectrum, mainly episodic diseases. Missense mutations of the gene cause familial hemiplegic 
migraine (FHM) and it is also likely to be involved in the more common forms of migraine. It 
was investigated whether the CACNA1A gene is also a candidate gene for CH. In this study 
an association analysis of an intragenic polymorphic (CA)n‐repeat with marker D19S1150 
and a (CAG)n‐repeat in the 3'UTR region was performed, in 75 patients with CH in Swedish 
population. But it was found that genotypes and allele frequencies were similarly distributed 
in patients and controls. Also linkage disequilibrium between the two markers was similar 
in patients and controls. And it was suggested that any significance of the CACNA1A gene 
in CH is unlikely [88]. Similarly Haan J et al. suggested that there is no involvement of the 
calcium channel gene (CACNA1A) mutations in a Dutch family with CH [89].
4. Genetic aspect of migraine
Migraine is an episodic and disabling neurological disorder affecting roughly 14% of the pop‐
ulation. The two most prevalent forms are migraine without aura (MO) and migraine with 
aura (MA). Migraine tends to run in families and has a strong genetic basis, with heritability 
estimates of 40–57%. In the rare monogenic subtype of migraine, familial hemiplegic migraine 
(FHM), three causative genes have been identified. There is, however, no significant asso‐
ciation between these genes and MO and/or MA. Many linkage studies and candidate gene 
studies have suggested causative genes in MO and MA, but few have been replicated. Recent 
attempts using genome‐wide association studies (GWAS) have yielded four single nucleo‐
tide polymorphisms (SNPs) that are significantly associated with migraine and recently, three 
additional SNPs have shown convincing association as well [90–93].
Recently, several studies have been used to identify genetic variants either causing migraine or 
conferring vulnerability to the disease. The array‐based technologies and second‐ generation 
DNA sequencing has provided novel analysis to genetic database. In general, rare variants 
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are sought by DNA sequencing in multigenerational families with many affected individuals. 
These studies were previously performed using a linkage approach, followed by refinement 
of the linkage region and targeted Sanger sequencing of candidate genes. On the other hand, 
genome‐wide association studies (GWAS) allowed the determination of the case‐control or 
family‐based association studies in large samples [93].
Many studies are conducted for understanding of molecular genetic basis of MA, MO and 
FHM well. Especially GWAS has given very important results for these diseases. The present 
work does not represent a systematic review but rather aims to provide thorough coverage of 
this area of investigation. Migraine can be part of known genetic disorders, displaying mul‐
tiple manifestations and often involving various organs.
Migraine is associated with some of genetic syndromes. These diseases are CADASIL cere‐
bral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, 
COL4A1 retinal arteriolar tortuosity and leukoencephalopathy, CRV cerebroretinal vasculop‐
athy, CSD cortical spreading depression, FASPS familial anticipated sleep phase syndrome, 
HERNS hereditary endotheliopathy with retinopathy, nephropathy, stroke, HVR hereditary 
vascular retinopathy, MELAS mitochondrial encephalomyopathy, lactic acidosis, stroke‐like 
episodes, RVCL retinal vasculopathy and cerebral leukodystrophy These disorders, though 
rare, may lead to a better comprehension of the mechanisms underlying more common forms 
of idiopathic migraine. Other forms of typical FHM due to mutations in novel FHM candi‐
date genes have been recently described. Mutations resulting in an FHM phenotype have 
been identified in the PRRT2 (proline‐rich transmembrane protein 2) gene, located on human 
chromosome 16p11 and encoding for an axonal protein associated with the exocytosis protein 
complex [94–99].
Studies shown that FHM is related to CACNA1A gene which encoded by 19p13, which pro‐
duces voltage‐dependent (P/Q) Cav 2.1 channel, α1A subunit Over 70 missense mutations 
with “gain of function” effect. ATP1A2 encoded by 1q21‐23 that produce to Na+‐K+ ATPase α2 
subunit responsible for FHM 2 disease. FHM3 is related to SCN1A gene. In conclusion, famil‐
ial forms of MA and in particular FHM, are due to rare inherited or sporadic genetic variants 
endowed with high penetrance. These mutations are affecting the transmembrane electro‐
chemical gradient by enhancing extracellular glutamate concentrations which are related with 
neuronal excitability [100, 101]. We can explain migraine‐associated genes in four groups and 
other effective mechanisms (Figure 2).
4.1. Candidate genes
(1) Neurological genes: This group candidate genes encode (a)ion channels (calcium chan‐
nel, voltage‐dependent, P/Q type, alpha 1A subunit [CACNA1A], voltage‐potassium inter‐
mediate/small conductance calcium‐activated channel and subfamily N, member 3 [KCCN3]) 
(b) Na+/K+‐ATPase subunits, (c) molecules involved in the synthesis, release and binding 
of neuropeptides (calcitonin gene‐related peptide) or neurotransmitters (glutamate, GABA, 
dopamine, serotonin) relevant to neuronal excitation and/or to nociception. Some case‐control 
association studies have yielded positive results, as known 5‐HT‐related genes, MAOA, dopa‐
mine‐related genes, although most studies have been negative especially for the former two 
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gene families. Nonetheless, a thorough screening of 150 brain‐expressed genes involved in 
ion homeostasis (channels, transporters, exchangers and accessory subunits) identified three 
genes encoding potassium channels associated with migraine, namely KCNK18, KCNG4 and 
KCNAB3 [100, 101].
(2) Vascular genes: These associated genes (ACE, MTHFR, NOTCH3, EDNRA) are involved 
in blood pressure regulation, endothelial cell function, vasoconstriction and vasodilation. 
Many vascular genes associated with migraine also confer risk for stroke and heart disease. 
These functional variants in some of vascular genes may cause migraine. Angiotensin con‐
verting enzyme (ACE) plays a key role in the maintenance of blood pressure and vessel wall 
tension. The D‐D (“deletion‐deletion”) common variant located in the ACE gene (human 
chr. 17q23) increases ACE enzymatic activity, as well as the frequency and duration of MA 
attacks. MTHFR is a key component of the remethylation of homocysteine to methionine, as it 
catalyzes the conversion of 5,10‐methylenetetrahydrofolate to 5‐methyltetrahydrofolate. Rare 
loss‐of‐function mutations in the MTHFR gene, located in human chromosome 1p36.22, can 
lead to hyperhomocysteinemia due to decreased enzyme activity [102–109].
NOTCH3 encodes for a transmembrane receptor regulating vascular development and dif‐
ferentiation during embryogenesis, as well as contributing to vascular integrity in adults. In 
addition to rare NOTCH3 mutations producing MA within the context of CADASIL, also 
common variants are significantly associated with migraine. Hence, NOTCH3 may play a 
broader role also in the pathogenesis of common migraine, well beyond rare forms associ‐
ated with CADASIL. Endothelial genes assessed for association with migraine encode for 
Figure 2. Genetic database of migraine disease.
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endothelin‐1 (EDN1), endothelin receptor type A and B (EDNRA and EDNRB), inducible NO 
synthase (NOS2), endothelial NO synthase (NOS3) and vascular endothelial growth factor 
(VEGF) [110–114].
(3) Hormonal genes: These group genes are related with estrogen and progesterone metabo‐
lism especially relating to menstrual migraine. However, results from studies of genetic asso‐
ciation between these genes and migraine were published in the later study, three estrogen 
receptor 1 (ESR1) haplotypes were significantly associated with the disorder (P < 0.05 or 0.01). 
In addition to ESR1, six other hormonal genes have been investigated, estrogen receptor 2 
(ESR2), progesterone receptor (PGR) androgen receptor (AR), follicle stimulating hormone 
receptor (FSHR), nuclear receptor interacting protein 1 (NRIP1) and cytochrome P450, family 
19, subfamily A, polypeptide 1 (CYP19A1) [115–119].
(4) Inflammatory genes: Recent studies shown that neurogenic inflammation, with activation 
of mast cells and macrophages accompanied by the release of proinflammatory cytokines 
may play an important role in the pathogenesis of migraine. Especially tumor necrosis factor 
alfa (TNF‐α) gene variants is positive associated with migraine [120, 121]
4.2. Family linkage studies and GWAS
Many GWAS and classical linkage studies have been performed for migraine either using a 
genome‐wide approach or targeting specific regions using microsatellite markers. Also, mito‐
chondrial dysfunction in migraine that increased influx of calcium increases oxidative stress, 
that muscle biopsy of patients with migraine may show mitochondrial abnormalities, that 
mtDNA polymorphisms may be increased in migraine patients and that riboflavin, coen‐
zyme‐Q, niacin and carnitine, all agents used in the treatment of MIDs, exhibit a beneficial 
effect for migraine [122].
Recent GWAS studies have shown four SNPs, located on chromosome 8q22.1, 2q37.1, 12q13.3 
and 1p36.32, which are associated with MA and/or MO. Although, some meta‐analysis con‐
firmed that the same results in independent populations. In another recent GWAS, three addi‐
tional SNPs located at 1q22 and 3p24. However, all of these associated studies shown that the 
moderate of change in risk for migraine. On the other hand, the pedigree‐based GWAS in an 
isolated population of Norfolk Island with a high prevalence of migraine and several novel 
variants in migraine susceptibility were identified [117–120].
4.3. Epigenetic
Epigenetics role of many complex diseases including migraine has aroused curiosity.
The effect of methylated DNA, methylated cytosines in the human D‐loop of mitochondrial 
DNA (mtDNA), acetylation have shown differences between healthy controls and neurode‐
generative and age‐related diseases. Given comorbidities with migraine and the suggestive 
link between mitochondrial dysfunction and the lowered threshold for triggering a migraine 
attack, mitochondrial methylation may be a new avenue to pursue. New epigenetic approach 
of to solve the complex background of neurological diseases are very important [121–124].
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The success of migraine genetic investigations will largely rely upon their capacity on one 
hand to apply the methodological approaches most apt to respond to each specific experimen‐
tal question on the other hand, on their capacity to integrate multiple levels of phenotypic, 
functional and genetic information, in accordance with the complexity of the disorder itself. 
Environmental factors, such as early and recent life events, hormones and inflammation, can 
indeed act upon a genetically vulnerable background to trigger the onset and determine the 
progression of the disease.
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